Searching for “mutant”-specific JAK2 inhibitors by targeting a predicted mechanism of activation of JAK2 kinase domain (JH1) by the V617F pseudokinase (JH2) mutation. A small molecule must interrupt the predicted F617-F595 interaction based on the demonstration that F595 (or an aromatic residue) is required for activation by the V617F mutation.